medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 6

<< Back Next >>

Ann Hepatol 2015; 14 (6)

A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma

Attallah AM, El-Far M, Abdel MCA, Omran MM, Farid K, Yahya RS, Saad EA, Albannan MS, Attallah AA, El Basuni MA, Ali IS, Abed SB, El Naggar MA

Language: English
References: 53
Page: 869-880
PDF size: 280.29 Kb.


ABSTRACT

Background and rationale for the study. Continuing search for suitable tumor-markers is of clinical value in managing patients with various malignancies. These markers may be presented as intracellular substances in tissues or may be released into the circulation and appear in serum. Therefore, this work is concerned with identification and quantitative determination of epithelial membrane antigen (EMA) and fibronectin and estimating their performances as surrogate markers for identifying hepatocellular carcinoma (HCC). Results. A total of 627 individuals constituted this study [fibrosis (F1-F3) = 217; cirrhosis = 191; HCC = 219]. Western-blot was used for identifying EMA and fibronectin in sera. As a result, a single immunoreactive band was shown at 130-kDa and 90-kDa corresponding to EMA and fibronectin, respectively. They were quantified using ELISA providing values in HCC higher than fibrosis or cirrhosis with a significant difference (P ‹ 0.0001). For identifying HCC, EMA showed 0.82 area under receiver-operating characteristic curve (AUC) with sensitivity = 70% and specificity = 78% while fibronectin yielded AUC = 0.70 with sensitivity = 67% and specificity = 82%. FEBA-Test comprising fibronectin and EMA together with total-bilirubin and AFP was constructed yielding AUC = 0.92 for identifying HCC from cirrhosis with sensitivity = 89% and specificity = 85%. FEBA-Test was then tested for differentiating HCC from fibrosis showing AUC = 0.97 with sensitivity = 90% and specificity = 89%. FEBA-Test enabled the correct identification of HCC patients with CLIP 0-1 and size ≤ 3 cm with AUC = 0.80 and AUC = 0.84, respectively, indicating its ability in identifying early HCC. Conclusions. A four-marker index may improve the early detection of HCC with a high degree of accuracy.


REFERENCES

  1. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-6.

  2. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-6.

  3. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.

  4. Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010; 12: 186-92.

  5. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999; 94: 2224-9.

  6. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36: S84-S92.

  7. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34: 603-5.

  8. Johnson PJ. Screening for hepatocellular carcinoma-answers to some simple questions. Am J Gastroenterol 2002; 97: 225-6.

  9. Lin DY, Liaw YF. Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis. J Gastroenterol Hepatol 2001; 16: 715-7.

  10. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004; 127: S108-S112.

  11. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001; 16: 553-9.

  12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.

  13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  14. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.

  15. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 840-5.

  16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.

  17. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.

  18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.

  19. Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol 2012; 56: 1171-80.

  20. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48(Suppl. 1): S20-S37.

  21. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.

  22. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001; 16: 1378-83.

  23. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 1987; 4: 357-63.

  24. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-8.

  25. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038-43.

  26. Attallah AM, El-Far M, Abdel Malak CA, Zahran F, Farid K, Omran MM, Zagloul H, et al. Evaluation of cytokeratin-1 in the diagnosis of hepatocellular carcinoma. Clin Chim Acta 2011; 412: 2310-5.

  27. Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK. Structural organization and classification of the human mucin genes. Front Biosci 2001; 6: D1192-D1206.

  28. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ. Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol 2005; 11: 4661-6.

  29. Davidson B, Babich J, Okeefe P, Styles J, Dean C. Circulating levels of epithelial membrane antigen in patients with breast or colorectal-cancer. Int J Oncol 1992; 1: 611-4.

  30. Ormerod MG, Steele K, Westwood JH, Mazzini MN. Epithelial membrane antigen: partial purification, assay and properties. Br J Cancer 1983; 48: 533-41.

  31. Sasaki M, Nakanuma Y. Expression of mucin core protein of mammary type in primary liver cancer. Hepatology 1994; 20: 1192-7.

  32. Cao Y, Karsten U, Otto G, Bannasch P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch 1999; 434: 503-9.

  33. Hendrick JC, Collette J, Claes S, Franchimont P. Epithelial membrane antigen (EMA) distribution in various biological fluids. Eur J Cancer Clin Oncol 1988; 24: 1589-94.

  34. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008; 7: 963-75.

  35. Lacunza E, Bara J, Segal-Eiras A, Croce MV. Expression of conserved mucin domains by epithelial tissues in various mammalian species. Res Vet Sci 2009; 86: 68-77.

  36. Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, Stanta G, Baralle FE. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J Cell Biol 2003; 162: 149-60.

  37. Dufour S, Duband JL, Kornblihtt AR, Thiery JP. The role of fibronectins in embryonic cell migrations. Trends Genet 1988; 4: 198-203.

  38. Dufour S, Duband JL, Humphries MJ, Obara M, Yamada KM, Thiery JP. Attachment, spreading and locomotion of avian neural crest cells are mediated by multiple adhesion sites on fibronectin molecules. Embo J 1988; 7: 2661-71.

  39. Proctor RA. Fibronectin: a brief overview of its structure, function, and physiology. Rev Infect Dis 1987; 9(Suppl. 49: S317-S321.

  40. Kosmehl H, Berndt A, Katenkamp D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Arch 1996; 429: 311-22.

  41. Fernandez-Garcia B, Eiro N, Marin L, Gonzalez-Reyes S, Gonzalez LO, Lamelas ML, Vizoso FJ. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 2014; 64: 512-22.

  42. Gorczyca W, Holm R, Nesland JM. Laminin production and fibronectin immunoreactivity in breast carcinomas. Anticancer Res 1993; 13: 851-8.

  43. Saito N, Nishimura H, Kameoka S. Clinical significance of fibronectin expression in colorectal cancer. Mol Med Rep 2008; 1: 77-81.

  44. Lin C-c, Yin M-c. Clinical significance of circulating IL-10 and fibronectin levels in hepatocellular carcinoma patients with HBV infection. BioMedicine 2012; 2: 122-6.

  45. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing f ibronectin expression. Hepatology 2009; 50: 490-9.

  46. Danen EH, Yamada KM. Fibronectin, integrins, and growth control. J Cell Physiol 2001; 189: 1-13.

  47. Iotsova V, Stehelin D. Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth Differ 1996; 7: 629-34.

  48. Salcedo R, Wasserman K, Patarroyo M. Endogenous fibronectin of blood polymorphonuclear leukocytes: stimulus-induced secretion and proteolysis by cell surface-bound elastase. Exp Cell Res 1997; 233: 33-40.

  49. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.

  50. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-5.

  51. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-21.

  52. Lai EC, Lau WY. Hepatocellular carcinoma presenting with obstructive jaundice. ANZ J Surg 2006; 76: 631-6.

  53. Ishida H, Matsuo S, Inoue Y. Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up. Rinsho Byori 2010; 58: 1065-72.




2020     |     www.medigraphic.com